Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information.
Overview and classification
Ketorolac is a potent nonselective COX-1/COX-2-inhibiting NSAID derived from a pyrrolizine carboxylic acid structure, not an oxicam. It treats selected moderately severe acute pain requiring analgesia at the opioid level, often after surgery. It is not an opioid, does not activate mu receptors and does not confer the absence of GI, renal or bleeding risks [1,2].
Pharmacology and pharmacokinetics
Reversible inhibition of COX reduces prostaglandin synthesis and pain sensitization, but also reduces gastric protection, renal prostaglandin-dependent blood flow and platelet thromboxane production. Ketorolac is administered by labeled IV, IM, oral, intranasal or ophthalmic formulations with different indications; it is highly protein bound, hepatically metabolized and renally eliminated in significant part [1].
Critical US five-day maximum
US systemic ketorolac labeling specifies a maximum combined treatment duration of five days for IV/IM and oral therapy in adults. Oral ketorolac is continuation treatment after IV or IM therapy when needed—not routine initiation. The former article’s statement of a seven-day IV limit was incorrect. Ketorolac is not indicated for minor or chronic painful conditions, and its systemic formulations are not labeled as routine pediatric oral therapy [2].
GI, renal and cardiovascular boxed warnings
Serious upper/lower GI hemorrhage, ulceration and perforation may occur without prodrome; avoid in patients with active/recent peptic ulcer or GI bleeding. Advanced renal impairment or volume depletion confers significant acute kidney injury risk. NSAID-associated cardiovascular thrombosis includes MI and stroke and may occur early. Ketorolac is contraindicated for perioperative CABG pain and prophylactic preoperative analgesia and in certain high-bleeding-risk conditions [2].
Bleeding and drug interactions
Ketorolac inhibits platelet function and is contraindicated with ongoing aspirin or other NSAIDs; probenecid and pentoxifylline are also contraindicated in US labeling. Combining with anticoagulants, antiplatelets, SSRIs or corticosteroids can increase bleeding risk. Dehydration, ACE inhibitors/ARBs, diuretics and older age increase kidney risk. Carefully review renal function, active bleeding and other medicines before use [1,2].
Pregnancy and monitoring
Ketorolac is contraindicated during labor/delivery under US labeling; other pregnancy-related NSAID cautions include fetal renal dysfunction from about 20 weeks and ductal constriction at about 30 weeks. Monitor for bleeding, hypotension, oliguria, edema and abdominal pain. Do not extend the course simply because early pain relief is satisfactory [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Ketorolac tromethamine tablets: boxed warning and prescribing information, 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=337afb4f-789f-4cac-817a-e4286664a71e
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.